This article is more than 5 years old. Information may no longer be current.

Phakic anterior chamber IOL caused minimal endothelial cell loss during clinical trials

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

SEATTLE — A phakic anterior chamber IOL has shown a low rate of endothelial cell loss in clinical trials to date, said Stephen S. Lane, MD.

Dr. Lane presented the average results of his procedures with Alcon’s anterior chamber phakic lens, which he said is in an early phase of clinical trials.

“We have to count endothelial cells obviously for clinical trials. To date, I have been able to place 14 of these lenses,” he told attendees here at the ASCRS Summer Refractive Congress. “At a 4-month period of time our average (endothelial cell loss) was 2%.”

The tunnel created for insertion is a little shorter than a typical phaco incision, and the IOL is loaded into a cartridge for insertion, Dr. Lane said.

“The haptics slowly unfold and it is ‘tacoed’ in the upward direction, so as the lens unfolds, it folds downward,” he explained.

This anterior chamber phakic IOL has a 6-mm optic, he noted.